These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 32399639)

  • 21. Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [
    Vogel MME; Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Mix M; la Fougère C; Eiber M; Christiansen H; Belka C; Grosu AL; Müller AC; Guckenberger M; Combs SE
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2328-2338. PubMed ID: 32179961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. (68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer : Early efficacy after primary therapy.
    Henkenberens C; von Klot CA; Ross TL; Bengel FM; Wester HJ; Merseburger AS; Vogel-Claussen J; Christiansen H; Derlin T
    Strahlenther Onkol; 2016 Jul; 192(7):431-9. PubMed ID: 27272755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salvage radiotherapy in patients affected by oligorecurrent pelvic nodal prostate cancer.
    Ingrosso G; Mariucci C; Tenti MV; Bini V; Alì E; Saldi S; Palumbo I; Bellavita R; Aristei C
    Clin Transl Oncol; 2020 Dec; 22(12):2236-2243. PubMed ID: 32418156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy-a multicenter retrospective study.
    Schmidt-Hegemann NS; Kroeze SGC; Henkenberens C; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Müller AC; Grosu AL; Combs SE; Christiansen H; Guckenberger M; Belka C
    Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1852-1863. PubMed ID: 32002591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metastasis-directed Therapy (SBRT) Guided by PET-CT
    Mazzola R; Francolini G; Triggiani L; Napoli G; Cuccia F; Nicosia L; Livi L; Magrini SM; Salgarello M; Alongi F
    Clin Genitourin Cancer; 2021 Jun; 19(3):230-236. PubMed ID: 32863189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of
    Walacides D; Meier A; Knöchelmann AC; Meinecke D; Derlin T; Bengel FM; Ross TL; Wester HJ; Derlin K; Kuczyk MA; von Klot CAJ; Christiansen H; Henkenberens C
    Strahlenther Onkol; 2019 May; 195(5):420-429. PubMed ID: 30610354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of relapse as determined by
    Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA
    Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer.
    Horn T; Krönke M; Rauscher I; Haller B; Robu S; Wester HJ; Schottelius M; van Leeuwen FWB; van der Poel HG; Heck M; Gschwend JE; Weber W; Eiber M; Maurer T
    Eur Urol; 2019 Oct; 76(4):517-523. PubMed ID: 30987843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience.
    Deek MP; Yu C; Phillips R; Song DY; Deville C; Greco S; DeWeese TL; Antonarakis ES; Markowski M; Paller C; Denmeade S; Carducci M; Walsh PC; Pienta KJ; Eisenberger M; Tran PT
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):948-956. PubMed ID: 31419509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row : Nodal oligorecurrent prostate cancer.
    Fodor A; Lancia A; Ceci F; Picchio M; Hoyer M; Jereczek-Fossa BA; Ost P; Castellucci P; Incerti E; Di Muzio N; Ingrosso G
    World J Urol; 2019 Dec; 37(12):2607-2613. PubMed ID: 29752513
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Henkenberens C; VON Klot CA; Ross TL; Bengel FM; Wester HJ; Katja H; Christiansen H; Derlin T
    Anticancer Res; 2017 Mar; 37(3):1273-1279. PubMed ID: 28314292
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Ahmadzadehfar H; Azgomi K; Hauser S; Wei X; Yordanova A; Gaertner FC; Kürpig S; Strunk H; Essler M
    J Nucl Med; 2017 Mar; 58(3):438-444. PubMed ID: 27660148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer.
    Mohan R; Kneebone A; Eade T; Hsiao E; Emmett L; Brown C; Hunter J; Hruby G
    Radiat Oncol; 2023 Aug; 18(1):127. PubMed ID: 37528487
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Marzec J; Becker J; Paulsen F; Wegener D; Olthof SC; Pfannenberg C; Schwenck J; Bedke J; Stenzl A; Nikolaou K; la Fougère C; Zips D; Müller AC
    Acta Oncol; 2020 Feb; 59(2):149-156. PubMed ID: 31559880
    [No Abstract]   [Full Text] [Related]  

  • 35.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
    Jilg CA; Drendel V; Rischke HC; Beck T; Vach W; Schaal K; Wetterauer U; Schultze-Seemann W; Meyer PT
    Theranostics; 2017; 7(6):1770-1780. PubMed ID: 28529650
    [No Abstract]   [Full Text] [Related]  

  • 37. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
    Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
    Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
    Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging.
    Meijer D; van Leeuwen PJ; Donswijk ML; Boellaard TN; Schoots IG; van der Poel HG; Hendrikse HN; Oprea-Lager DE; Vis AN
    BJU Int; 2022 Jan; 129(1):54-62. PubMed ID: 34028165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence.
    Tamburo M; Buffettino E; Pepe P; Marletta G; Pepe L; Cosentino S; Ippolito M; Pennisi M; Marletta F
    Anticancer Res; 2024 May; 44(5):2205-2210. PubMed ID: 38677723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.